Privette Vinnedge Lab

Publications

Peters, EJ; Gardner, KL; Privette Vinnedge, LM. All hands on DEK: structural insights into a unique histone modifier and chromatin remodeler. Epigenetics and Chromatin. 2026.

Johnstone, ME; Leck, AL; Lange, TE; Wilcher, KE; Shephard, MS; Paranjpe, A; Schutte, S; Wells, SI; Kappes, F; Salomonis, N; Privette Vinnedge, LM. DEK promotes mammary hyperplasia and is associated with H3K27me3 epigenetic modifications. Life Science Alliance. 2025; 8(9).

Wilcher, KE; Page, ERH; Privette Vinnedge, LM. The impact of the chromatin binding DEK protein in hematopoiesis and acute myeloid leukemia. Experimental Hematology. 2023; 123:18-27.

Greene, AN; Nguyen, ET; Paranjpe, A; Lane, A; Privette Vinnedge, LM; Solomon, MB. In silico gene expression and pathway analysis of DEK in the human brain across the lifespan. European Journal of Neuroscience. 2022; 56(6):4720-4743.

Hegde, S; Gasilina, A; Wunderlich, M; Lin, Y; Buchholzer, M; Krumbach, OHF; Akbarzadeh, M; Ahmadian, MR; Seibel, W; Zheng, Y; Perentesis, JP; Mizukawa, BE; Vinnedge, LP; Cancelas, JA; Nassar, NN. Inhibition of the RacGEF VAV3 by the small molecule IODVA1 impedes RAC signaling and overcomes resistance to tyrosine kinase inhibition in acute lymphoblastic leukemia. Leukemia. 2022; 36(3):637-647.

Muhammad, B; Parks, LG; Komurov, K; Privette Vinnedge, LM. Defective transcription elongation in human cancers imposes targetable proteotoxic vulnerability. Translational Oncology. 2022; 16:101323.

Greene, AN; Solomon, MB; Privette Vinnedge, LM. Novel molecular mechanisms in Alzheimer's disease: The potential role of DEK in disease pathogenesis. Frontiers in Aging Neuroscience. 2022; 14:1018180.

Singh, N; Romick-Rosendale, L; Watanabe-Chailland, M; Privette Vinnedge, LM; Komurov, K. Drug resistance mechanisms create targetable proteostatic vulnerabilities in Her2+ breast cancers. PLoS ONE. 2022; 17(12):e0256788.